AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Change in Directorate 13 Jul - Anil Raghavan to become Managing Director and CEO from Aug 11, 2026; Dr. Rajamannar Thennati retires Aug 10, 2026.
Source: Bse
Sun Pharma Advanced Research Company Limited (SPARC)
Micro CapPharma stocks · Micro cap · NSE
Sun Pharma Advanced Research Company Limited (SPARC) is an Indian listed company. The provided document is an administrative notice regarding an upcoming investor presentation scheduled for January 08, 2026.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals17 Oct 2026 · screener
Latest result16 Aug, 12:32 am IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
69BullishSMA20 -1.1% / mo · MACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 49
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
SPARCD candles · FIT view+32.9%Latest close ₹185.07 on 2026-10-19
Bar
-2.6%
RSI
41
MACD hist
-0.66
52W pos
43%
2026-10-19O ₹190.00H ₹191.42L ₹184.30C ₹185.07Vol 3.9L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
SPARCNifty PharmaNifty 500
- SPARC
- -18.7%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -13.1 pp
Chart stats
19 Oct 2026- From 52W high
- -36.0%
- 52W range position
- 43%
- ATR (14)
- 4.5%
- Volume vs 20D
- 0.38x
- Avg traded value
- ₹20.2 Cr
- 20D price channel
- ₹182.5 - ₹212
₹289
₹108 - ₹289
₹8.3
Latest completed session
20-session average
40.5% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend supports entry, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · FAIR VALUE56
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Average45
Revenue +300.0% · PAT NDF YoY
Technical
Bullish69
Price trend and sector-relative-strength timing.
Valuation
Legacy model+11.2%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence65
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Average · 45/100Rev +300% YoY · margin expansion
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹40 Cr | +300.0% | -97.8% |
| EBITDA | ₹-34 Cr | +34.6% | -101.9% |
| Operating margin | -85.0% | +45500 bps | -18100 bps |
| PAT | ₹-21 Cr | NDF | -101.2% |
| PAT margin | -52.5% | +46750 bps | -14754 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 3.83
- P/B
- 4.58
- EV/EBITDA
- 4.11
- Market Cap
- 6122.00Cr
Profitability
- ROE
- 279.00%
- ROCE
- 164.00%
- ROA
- 72.96%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- -8.00%
- EPS 5Y
- -8.00%
- Revenue 3Y
- -16.00%
- EPS 3Y
- -20.00%
Balance Sheet
- Debt/Equity
- 0.42
- Interest Coverage
- 44.92×
- Altman Z
- 7.99
- Book Value
- 41.30
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 0/5
- OCF
- -239.00 Cr
- EPS TTM
- 48.81
Shareholding
- Promoter Hold
- 65.68%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 45%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 1,879+2509.7% vs prev
Net Profit
₹ CrLatest: 1,553+552.8% vs prev
Return on Equity
%Latest: 116+137.5% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
NeutralTrend is undirectional — long-term uptrend intact. RSI 41.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~1.1% over last month) — short-term momentum negative.
- RSI(14) at 41 — sideways, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- 36% off 52W high · 71% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
80
RS percentile
Stage 1 Base / Transition
1M return
-4.6%
3M return
-18.7%
6M return
+28.9%
1Y return
+30.1%
RS 1D
-2
RS 20D
-3
Sector rank
#1
Industry rank
#17
Stage evidence
- Price is within 3.9% of the 30-week proxy.
- The 30-week proxy changed +5.2% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price above
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 144.74-0.88%
RS vs Nifty 500145
Valuation & peers
U-Score 56 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 56 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Deep Value
Fundamental score breakdown
U band · FAIR VALUEValuation23/30
Growth3/25
Quality20/20
Balance Sheet9/15
Cash Flow0/10
Piotroski
4/9 (+1)
Penalties
0
Raw sum
56
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
56/100 · legacy band FAIR VALUE
Positive drivers
- Fair-value margin of safety is positive at 11.2%.
- Quality contributes 20/20 to the score.
- Valuation contributes 23/30 to the score.
Main drags
- Cash flow is weaker at 0/10; verify the latest quarterly trend.
- Growth is weaker at 3/25; verify the latest quarterly trend.
- Balance sheet is weaker at 9/15; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
3.8
PB
4.6
EV/EBITDA
4.1
ROE
279.0%
ROCE
164.0%
FCF Yield
—
Debt/Equity
0.4
MoS
+11.2%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
56
Previous: 56
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
+11.2%
Previous: +11.2%
Score history
12 stored score snapshots. Latest stored move: +2 points.
20 Oct 2026
v4.3-runtime-valuation
56
54
54
54
54
54
54
54
54
54
54
56
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹212.97
+13.1% MoS
Growth-justified P/E
4.3
Growth-justified Value
₹208.42
+11.2% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
SUPRIYA
Micro
Supriya Lifescience Limited
Healthcare Services
match 166
52
35.9
19.1%
+19%
FAIR VALUE
STAR
Micro
Strides Pharma Science Limited
Healthcare Services
match 165
69
16.6
20.0%
+65%
UNDERVALUED
SENORES
Small
Senores Pharmaceuticals Limited
Healthcare Services
match 164
35
48.2
13.4%
-2%
WATCHLIST
ORCHPHARMA
Small
Orchid Pharma Limited
Healthcare Services
match 164
33
320.0
1.5%
-846%
WATCHLIST
KPL
Small
Kwality Pharmaceuticals Limited
Healthcare Services
match 162
54
46.3
22.6%
+4%
FAIR VALUE
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Where growth can come from, and what can break the case
Thesis intactReviewed 2026-06-11T07:23:21.842Z
Management commentary snapshot
No financial or operational results were disclosed in the provided investor presentation cover letter.
The provided document is a cover letter for an investor presentation and contains no financial results, operational data, or management commentary. Therefore, no assessment of the company's thesis can be made based on this document.
Management accountability
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Analyst reading lens
Compare YOY
The document does not contain any financial or operational results, making it impossible to determine a relevant comparison basis. A default of YoY is used, but no data supports this.
Thesis monitor
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust Score
65Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 45th percentile of the scored universe and 33rd percentile within Pharma. Main check: cash conversion is weak at 28/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
47 docs text-extracted · 16 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
45th percentile
overall median 67 · Pharma: 33rd pctile, median 70 · Micro: 27th pctile, median 73
Evidence depth
Financial-only
47 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
28
weak · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
82
strong · capital discipline
Results
45
watch · quarterly consistency
Trust positives
- ▸Promoter holding is 65.7%.
- ▸Promoter pledge is zero.
- ▸ROCE is 164%.
Trust risks
- ▸Operating cash flow is negative at ₹-239 Cr.
- ▸Only 0 years of positive FCF.
- ▸OPM spread across recent quarters is 932%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Sun Pharma Advanced Research Company Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual reportAug 2026
Aug 2026 · Notice Of 21St Annual General Meeting To Be Held On August 10, 2026 Along With The Annual Report For FY 26 16 Jul
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 11 Aug
Source: Bse
AnnouncementJul 2026
Jul 2026 · Announcement under Regulation 30 (LODR)-Change in Management 26 Jun - SPARC announces two retirements and Prasanna Deshmukh’s appointment effective June 30-July 1, 2026.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 17 Jul - Newspaper Advertisement of 21st Annual General Meeting of Company and related information
Source: Bse
Annual report
Business Responsibility and Sustainability Reporting (BRSR) 16 Jul - SPARC submitted FY2025-26 BRSR with the annual report ahead of the 21st AGM.
Source: Bse
Annual report
Reg. 34 (1) Annual Report. 16 Jul
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 9 Jul - Newspaper Advertisement- 21st Annual General Meeting of the Company
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Monitoring Agency Report 10 Aug - Q1 FY27 monitoring report for ₹599.98 crore warrants issue shows no deviation and full loan repayment use.
Source: Bse
AnnouncementMay 2026
May 2026 · Announcement under Regulation 30 (LODR)-Allotment 19 May - On May 19, 2026, SPARC allotted 3.85 crore warrants to Shanghvi Finance at ₹155.80 each, receiving ₹149.99 crore.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 20 May
Source: Bse
Announcement
Update On PDP-716 NDA 19 May - Ocuvex Therapeutics received FDA CRL for PDP-716 NDA due to manufacturing facility inspection findings.
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.